Results 81 to 90 of about 466,978 (291)

ON THE DOLICHOPODIDAE (DIPTERA: EMPIDOIDEA) FROM SERBIA [PDF]

open access: yes, 2016
The data on Dolichopodidae from Serbia are reviewed. New records resulting from short-term visits to Serbia in 2014 and 2015 are presented. Of the 24 species collected, 14 are recorded for the first time for Serbia.
Grichanov, Igor Ya.
core   +1 more source

Signatures of Unconventional Magnetism in the Layered Metallic Ferromagnet LaCrSb3 From Ferromagnetic Resonance Spectroscopy

open access: yesAdvanced Physics Research, EarlyView.
ABSTRACT LaCrSb3${\rm LaCrSb}_{3}$ is a metallic ferromagnet with a layered crystal structure demonstrating intriguing electronic and magnetic properties, such as large anomalous Hall effect, strong canting of the spin lattice, and a peculiar spin‐reorientation transition.
J. J. Abraham   +7 more
wiley   +1 more source

Economic crisis and its consequences on the living standard and development of the agriculture in Serbia [PDF]

open access: yes
The economic crisis had transferred to Serbia at the end of 2008, causing the economic growth slowdown and macroeconomic stability endangerment. Agriculture, the strategic branch of national economy was affected as well, and despite favourable climatic ...
Lana, Nastic, Marko, Jelocnik
core  

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Inflation Targeting With Special Review on Appliction in Serbia [PDF]

open access: yes
Inflation targeting represents monetary regime primarily applied in New Zealand in 1989. Since then, this regime has extended into over 30 countries and it is recommended by International Monetary Fund within its business arrangements in last couple of ...
Nikola Fabris
core  

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Analysis of the Circular Economy Performance of the European Union and Serbia [PDF]

open access: yesRevista de Management Comparat International
Recently, due to its character, more and more attention has been paid to the application of the circular economy principle at the level of the national economy and in all sectors.
Radojko LUKIC
doaj   +1 more source

Report No. 8: Evaluation of the Active Labor Market Program "Beautiful Serbia" [PDF]

open access: yes
Final report on behalf of the United Nations Development Program (UNDP) Serbia and Montenegro, Bonn 2006 (84 pages)
Rinne, Ulf, Bonin, Holger
core  

The Importance of Geopolitics and National Logistics for the Security of the Republic of Serbia in Emergency Situations [PDF]

open access: yes
This research examines the attitudes of a targeted group of respondents (N=107) concerning emergency situations, with a particular focus on the Republic of Serbia and the critical role of national logistics in ensuring national security.
Stekić, Nenad, Stanojević, Petar
core   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Home - About - Disclaimer - Privacy